Cargando…
Treatment Outcomes of Novel Targeted Agents in Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-Analysis
Most chronic lymphocytic leukemia patients experience a relapse or become refractory to treatment with conventional chemotherapeutic agents. The network meta-analysis assesses the relative efficacy of novel targeted agents for the treatment of a relapse or refractory chronic lymphocytic leukemia. A...
Autores principales: | Chen, Po-Huang, Ho, Ching-Liang, Lin, Chin, Wu, Yi-Ying, Huang, Tzu-Chuan, Tu, Yu-Kang, Lee, Cho-Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572611/ https://www.ncbi.nlm.nih.gov/pubmed/31126075 http://dx.doi.org/10.3390/jcm8050737 |
Ejemplares similares
-
A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia
por: Lee, Cho-Hao, et al.
Publicado: (2020) -
Management of relapsed/refractory Chronic Lymphocytic Leukemia
por: Woyach, Jennifer A.
Publicado: (2022) -
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Odetola, Oluwatobi, et al.
Publicado: (2023) -
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
por: Shustik, C., et al.
Publicado: (2017) -
Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)